Načítá se...
Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R(x)EACH study
BACKGROUND: The R(x)EACH randomized trial demonstrated that community pharmacist prescribing and care reduced the risk for cardiovascular (CV) events by 21% compared to usual care. OBJECTIVE: To evaluate the economic impact of pharmacist prescribing and care for CV risk reduction in a Canadian setti...
Uloženo v:
| Vydáno v: | Can Pharm J (Ott) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6610508/ https://ncbi.nlm.nih.gov/pubmed/31320960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1715163519851822 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|